Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index; 24 of the 32 sources its claims cite were checked for support.

NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy

Open access

Abstract

eIF4A-targeted translational inhibitors, such as silvestrol and its analogues, have emerged as strong anticancer therapies. Here, we tested the efficacy of eIF4A inhibition across a large and diverse panel of cancer cell lines and found B cell lymphomas to be the most sensitive group. Moreover, we performed a genetic screen and identified NRF2 activation as a major mechanism of resistance to silvestrol and related eIF4A inhibitors. Mechanistically, NRF2 activation broadly increases protein synthesis, and this effect is more pronounced on specific mRNAs that require eIF4A for translation. Finally, blocking NRF2 function by preventing its deglycation restores silvestrol sensitivity in cells that harbor NRF2 activation.

Overview

CoChat Summary

## TL;DR

This paper shows that the eIF4A inhibitor CR-1-31 B is highly active against aggressive B cell lymphomas, with nanomolar potency and in vivo tumor growth inhibition. It also identifies NRF2 activation as a major resistance mechanism and shows that FN3K loss can restore sensitivity.

## Key findings

  • In a DepMap-based screen of 183 cancer cell lines, lymphoma cells were the most sensitive to CR-1-31 B; in aggressive DLBCL lines, IC50 values ranged from <1 nM (suDHL-4) to 5 nM (SuDHL-10, Ly8, and TMD8).
  • In vivo, CR-1-31 B treatment impaired growth of suDHL-6 xenografts (n = 10, p < 0.05) and a patient-derived MYC+/BCL2+ DLBCL xenograft (n = 5, p < 0.05), with no weight loss or mortality reported.
  • A genome-wide CRISPR/Cas9 screen in FL5-12 cells identified KEAP1, CUL3, and CAND1 as resistance-linked hits; loss of these NRF2 repressors reduced silvestrol sensitivity, and NRF2 knockdown restored wild-type sensitivity.
  • NRF2 activation increased global protein synthesis and specifically boosted translation of eIF4A-dependent mRNAs such as MYC and BCL2; in Keap1-edited FL5-12 cells, the eIF4A-dependent reporter increased 1.5-fold (`n = 3, p < 0.05`), and silvestrol’s suppression of MYC/BCL2 was largely blunted.
  • FN3K inactivation reversed NRF2-driven resistance: in Fn3k-proficient cells, DLS induced about a 6-fold increase in Nqo1, which dropped by about 50% with Fn3k editing; Fn3k silencing also largely reversed silvestrol resistance in Keap1-edited cells.

## Methods

  • The study combined a large-scale drug sensitivity screen (183 cell lines), in vitro viability assays, AHA metabolic labeling, luciferase reporter assays, qPCR/immunoblotting, CRISPR/Cas9 genetic editing and genome-wide screen, and in vivo xenograft models.
  • The CRISPR screen used FL5-12 cells with doxycycline-inducible Cas9 and a genome-wide library of about 90,000 sgRNAs targeting ~19,000 genes, followed by three cycles of silvestrol (10 nM) selection versus DMSO control.
  • The paper also analyzed DepMap data, used a 34-patient DLBCL tissue microarray for IHC, and assessed significance with DESeq/DESeq2 and Welch-corrected t tests.

## Limitations

  • The paper states that NRF2-activating lesions are rare in lymphoma, although frequent in advanced solid tumors; this limits how broadly the resistance mechanism may explain lymphoma response specifically.
  • The text makes evident that several key conclusions come from cell lines and xenografts, with only a small patient tissue cohort (n = 34) for IHC; this is an evident limitation because clinical validation is limited.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cancers13040639

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Single agent activity of a synthetic eIF4A inhibitor across multiple tumor types. (A) CR-1-31 B sensitivity profile across 770 cell lines generated from the DepMap database; the data are represented as the means of area under the drug response curve (AUC) for indicated cancer types; (B) violin plot depicting CR-1-31 B concentration, which leads to 50% growth inhibition (GI50) in 183 different cancer lines; (C) flow cytometry to measure AHA incorporation in DMSO or silvestrol treated (10 nM, 1 h) suDHL-6 cells; (D) immunoblot analysis to measure MYC and BCL2 expression from DMSO or silvestrol treated (24 h) human lymphoma cells, as indicated. Uncropped immunoblot images present in Figure S5; (E) tumor volumes of subcutaneously engrafted MYC+/BCL2+ suDHL-6 after treatment with vehicle or CR-1-31 B; data are shown as mean and standard deviation (s.d.) of tumor volumes ~28 days post implantation from n = 10 mice; (F,G) tumor volumes at day 42 (F) and growth kinetics (G) of MYC+/BCL2+ patient-derived DLBCL cells engrafted in NSG (NOD scid gamma) mice and treated with either vehicle or CR-1-31 B, as indicated; means of tumor volumes are plotted and error bars represent s.d. from n = 5 mice. * represents p-value < 0.05.
Figure 1 Single agent activity of a synthetic eIF4A inhibitor across multiple tumor types. (A) CR-1-31 B sensitivity profile across 770 cell lines generated from the DepMap database; the data are represented as the means of area under the drug response curve (AUC) for indicated cancer types; (B) violin plot depicting CR-1-31 B concentration, which leads to 50% growth inhibition (GI50) in 183 different cancer lines; (C) flow cytometry to measure AHA incorporation in DMSO or silvestrol treated (10 nM, 1 h) suDHL-6 cells; (D) immunoblot analysis to measure MYC and BCL2 expression from DMSO or silvestrol treated (24 h) human lymphoma cells, as indicated. Uncropped immunoblot images present in Figure S5; (E) tumor volumes of subcutaneously engrafted MYC+/BCL2+ suDHL-6 after treatment with vehicle or CR-1-31 B; data are shown as mean and standard deviation (s.d.) of tumor volumes ~28 days post implantation from n = 10 mice; (F,G) tumor volumes at day 42 (F) and growth kinetics (G) of MYC+/BCL2+ patient-derived DLBCL cells engrafted in NSG (NOD scid gamma) mice and treated with either vehicle or CR-1-31 B, as indicated; means of tumor volumes are plotted and error bars represent s.d. from n = 5 mice. * represents p-value < 0.05.CC BY · PubMed Central
Figure 2 Genome-wide CRISPR screen identifies loss of NRF2 regulators as a cause of resistance to eIF4A inhibition. (A) Schematic of the genome-side CRIPSR screen designed to identify resistance mechanisms to eIF4A inhibitor; (B) change in guide RNA representation in silvestrol-treated cells (n = 3) relative to those treated with DMSO (n = 3); (C) viability of FL5-12 cells transduced with sgRNAs targeting GFP, Keap1, or Cul3 and treated with either DMSO or silvestrol (48 h) as indicated; data are plotted as mean and s.d. from n ≥ 2; (D) Nrf2 proficient and deficient FL5-12 cells with or without Keap1 editing were treated with silvestrol as indicated, and cell viability was measured 48 h post treatment; error bars represent s.d. from n = 5; (E) cell viability of control and NRF2E79V expressing suDHL-6 lymphoma cells treated with silvestrol as indicated; error bar is s.d. from 3 replicates; (F) NRF2 proficient and deficient Ly19 cells were treated with silvestrol as indicated and cell viability was measured 48 h post treatment; data represent mean and s.d. from n = 3; (G) waterfall plot of silvestrol or CR-1-31 B IC50 values for indicated NRF2 wild-type (black) or mutant (red) cell lines; error bars represent s.d. from n ≥ 3; (H) correlation between CR-1–31 B sensitivity and expression of the NRF2 target gene NQO1 derived using DepMap database (n = 770). ns = significant and * represents p-value < 0.05.
Figure 2 Genome-wide CRISPR screen identifies loss of NRF2 regulators as a cause of resistance to eIF4A inhibition. (A) Schematic of the genome-side CRIPSR screen designed to identify resistance mechanisms to eIF4A inhibitor; (B) change in guide RNA representation in silvestrol-treated cells (n = 3) relative to those treated with DMSO (n = 3); (C) viability of FL5-12 cells transduced with sgRNAs targeting GFP, Keap1, or Cul3 and treated with either DMSO or silvestrol (48 h) as indicated; data are plotted as mean and s.d. from n ≥ 2; (D) Nrf2 proficient and deficient FL5-12 cells with or without Keap1 editing were treated with silvestrol as indicated, and cell viability was measured 48 h post treatment; error bars represent s.d. from n = 5; (E) cell viability of control and NRF2E79V expressing suDHL-6 lymphoma cells treated with silvestrol as indicated; error bar is s.d. from 3 replicates; (F) NRF2 proficient and deficient Ly19 cells were treated with silvestrol as indicated and cell viability was measured 48 h post treatment; data represent mean and s.d. from n = 3; (G) waterfall plot of silvestrol or CR-1-31 B IC50 values for indicated NRF2 wild-type (black) or mutant (red) cell lines; error bars represent s.d. from n ≥ 3; (H) correlation between CR-1–31 B sensitivity and expression of the NRF2 target gene NQO1 derived using DepMap database (n = 770). ns = significant and * represents p-value < 0.05.CC BY · PubMed Central
Figure 3 NRF2 broadly augments protein production and disproportionately increases eIF4A-dependent translation of MYC and BCL2. (A) AHA labeling to determine global translation in wild-type, Keap1, or Cul3 edited FL5-12 cells, as indicated; data are mean and s.d. from n = 4; (B) AHA labeling to determine global translation in Nrf2 proficient and deficient FL5-12 cells with or without Keap1 editing, as indicated; (C) translational efficiency of GQ-luciferase reporter in unedited and Keap1 edited FL5-12 cells; data are represented as the ratio of luciferase (encoded by transcript with 4 tandem GQ elements) to β-galactosidase (encoded by transcript without GQ elements) and plotted as means and s.d. from n = 3 replicates; (D) lysates from Keap1 proficient and deficient FL5-12 cells treated with DMSO or silvestrol (10 nM, 24 h) were immunoblotted and probed with indicated antibodies; (E) lysates from wild type, Cul3, or Keap1-edited FL5-12 cells treated with DMSO or silvestrol (10 nM, 24 h) were immunoblotted and probed with indicated antibodies; (F) lysates from mCherry or NRF2E79V expressing suDHL-4 cells treated with silvestrol (48 h) or not, as indicated, were immunoblotted and probed with indicated antibodies. Original immunoblot images are available in Figure S6. * represents p-value < 0.05.
Figure 3 NRF2 broadly augments protein production and disproportionately increases eIF4A-dependent translation of MYC and BCL2. (A) AHA labeling to determine global translation in wild-type, Keap1, or Cul3 edited FL5-12 cells, as indicated; data are mean and s.d. from n = 4; (B) AHA labeling to determine global translation in Nrf2 proficient and deficient FL5-12 cells with or without Keap1 editing, as indicated; (C) translational efficiency of GQ-luciferase reporter in unedited and Keap1 edited FL5-12 cells; data are represented as the ratio of luciferase (encoded by transcript with 4 tandem GQ elements) to β-galactosidase (encoded by transcript without GQ elements) and plotted as means and s.d. from n = 3 replicates; (D) lysates from Keap1 proficient and deficient FL5-12 cells treated with DMSO or silvestrol (10 nM, 24 h) were immunoblotted and probed with indicated antibodies; (E) lysates from wild type, Cul3, or Keap1-edited FL5-12 cells treated with DMSO or silvestrol (10 nM, 24 h) were immunoblotted and probed with indicated antibodies; (F) lysates from mCherry or NRF2E79V expressing suDHL-4 cells treated with silvestrol (48 h) or not, as indicated, were immunoblotted and probed with indicated antibodies. Original immunoblot images are available in Figure S6. * represents p-value < 0.05.CC BY · PubMed Central
Figure 4 FN3K is required for NRF2-driven silvestrol resistance. (A) Schematic showing the regulatory role of glucose dependent glycation and FN3K catalyzed deglycation in NRF2 function; (B) expression of the NRF2 target gene Nqo1 in FL5-12 cells transduced with control or Fn3k specific sgRNA/Cas9 treated with DMSO or NRF2 activator DLS, as indicated; error bars represent s.d. from n = 3; (C) cell viability of Fn3k-proficient and deficient FL5-12 cells, with or without Keap1 editing treated with DMSO or silvestrol (48 h), as indicated; error bars represent s.d. from n = 5; (D) FN3K-proficient and deficient Ly19 cells were treated with DMSO or silvestrol (48 h), as indicated, and cell viability was measured; error bars are s.d. from 3 replicates; (E) FN3K-proficient and deficient Ly19 cells were treated with DMSO or silvestrol (2.5 nM) and cell viability was measured after 48 and 72 h post treatment; error bars are s.d. from n = 3. * represents p-value < 0.05.
Figure 4 FN3K is required for NRF2-driven silvestrol resistance. (A) Schematic showing the regulatory role of glucose dependent glycation and FN3K catalyzed deglycation in NRF2 function; (B) expression of the NRF2 target gene Nqo1 in FL5-12 cells transduced with control or Fn3k specific sgRNA/Cas9 treated with DMSO or NRF2 activator DLS, as indicated; error bars represent s.d. from n = 3; (C) cell viability of Fn3k-proficient and deficient FL5-12 cells, with or without Keap1 editing treated with DMSO or silvestrol (48 h), as indicated; error bars represent s.d. from n = 5; (D) FN3K-proficient and deficient Ly19 cells were treated with DMSO or silvestrol (48 h), as indicated, and cell viability was measured; error bars are s.d. from 3 replicates; (E) FN3K-proficient and deficient Ly19 cells were treated with DMSO or silvestrol (2.5 nM) and cell viability was measured after 48 and 72 h post treatment; error bars are s.d. from n = 3. * represents p-value < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 1 Not valid · 2 Not checked · 32 Own results and interpretations

24 more claims · 3 with their cited sources checked

Create a free account to see all 48 claims and to verify the 3 references still open.

See all claims — free account
  • Probably not a substantial claim. 7
  • It may state two separate claims as one. 13
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 43 references

Cited by

See all 27

Metadata

Authors
Sanghvi, V. R., Mohan, P., Singh, K., Cao, L., Berishaj, M., Wolfe, A. L., Schatz, J. H., Lailler, N., de Stanchina, E., Viale, A., & Wendel, H.-G.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Department of Antitumor Assessment Core and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Corresponding author
Sanghvi, Viraj R.
Venue
Cancers
Publisher
MDPI AG
Published
2021-02-05
Volume
13
Issue
4
Pages
639
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3128657146
Cited by
27
References
43
Citations by year
2026: 3 · 2025: 3 · 2024: 7 · 2023: 6 · 2022: 5 · 2021: 3
FWCI
1.65
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
Funders
National Cancer Institute (P30CA008748, P50CA217694, P30CA240139)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
Keywords
Nrf2, silvestrol, drug resistance, B-cell lymphoma, Keap1, CUL3, CAND1, protein glycation, translational regulation, CRISPR-Cas9 screen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. https://app.cochat.ai/papers/10.3390/cancers13040639
The paper
Sanghvi, V. R., Mohan, P., Singh, K., Cao, L., Berishaj, M., Wolfe, A. L., Schatz, J. H., Lailler, N., de Stanchina, E., Viale, A., & Wendel, H.-G. (2021). NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. Cancers. https://doi.org/10.3390/cancers13040639

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.